Introduction
Compared to other enzyme families such as cytochromes P450, pharmacogenetic studies of human sulfotransferases (SULTs) in relation to drug response are fairly limited. Previously, human platelets have been employed as a source of enzyme for human pharmacogenetic studies due to their expression of two of the most common SULTs, SULT1A1 and SULT1A3 (Sundaram et al., 1989b; Weinshilboum, 1990; Weinshilboum and Aksoy, 1994) . In the past few years, the technological breakthroughs associated with completion of the Human Genome Project, along with the identification of single-nucleotide polymorphisms (SNPs), have made possible the exploration of genetic factors influencing SULT enzymatic activity. Subsequently, recent studies by several investigators have demonstrated the physiological relevance of SULT genotype.
Biotransformation of compounds via sulfation (the correct term is sulfonation, although it is not commonly used) was first described in the mid-1800s, but elucidation of the biochemistry of this metabolic pathway has mainly occurred during the last half of this century. SULTs involved in Phase II biotransformation of endoand xenobiotics are cytosolic, although there are membrane bound SULTs that are responsible for catalysing the sulfation of protein tyrosyl residues and polysaccharides (Huttner, 1988; Hashimoto and Hirschberg, 1992) . These sulfotransferase isoforms are genetically distinct from cytosolic SULTs; they have no xenobiotic-metabolizing function and will not be discussed in this review. Hereafter, the SULT designation will refer to the cytosolic SULTs.
SULTs belong to a superfamily of genes that are divided into two subfamilies, the phenol SULTs (SULT1) and the hydroxysteroid SULTs (SULT2). A third, less characterized subfamily of brain-specific SULT has also been described (Liyou et al., 2003) . SULT enzymes have a widespread tissue distribution and are expressed in the liver, lung, brain, skin, platelets, breast, kidney and gastrointestinal tissue (Cappiello et al., 1989; Zou et al., 1990; Kudlacek et al., 1995; Falany and Falany, 1996; Hume et al., 1996) . The biological function of SULT enzymes is to catalyse the transfer of the sulfonyl group from 3 0 -phosphoadenosine 5 0 -phosphosulfate (PAPS) to the hydroxyl, sulfhydryl, amino or N-oxide groups of various substrates. SULTs have broad overlapping substrate specificities, but can be distinguished to some extent by their particular affinities for substrates, their thermal stability and their sensitivity to inhibition by various agents. To date, at least 11 different SULT enzymes have been identified (reviewed in Glatt, 2000) . SULT pharmacogenetics have been the subject of two recent reviews (Nagata and Yamazoe, 2000; Glatt and Meinl, 2004) . The current review will focus on recent findings in the predominant member of two subfamilies, SULT1A1 and SULT2A1.
SNPs have been identified in most of the SULT isoforms. In some instances, these SNPs are rare, and, while they might have a significant influence on drug metabolism in the individual, the low occurrence in the population make them unsuitable for pharmacogenetic studies. SNPs in other isoforms occur commonly in humans and are associated with altered enzymatic activity. The allele frequency of some functional polymorphisms differs by ethnicity, which could contribute to differential drug responses between ethnic groups. Functional SNPs in SULT enzymes have the potential to alter the pharmacokinetic/pharmacodynamic profiles of drugs metabolized by SULTs, thus altering the efficacy of therapy.
PAPS, the obligatory cosubstrate of sulfotransferases, is synthesized from ATP and inorganic sulfate by a bifunctional enzyme, 3 0 -phosphoadenosine 5 0 -phosphosulfate synthetase (PAPSS). There are two isoforms of PAPSS, PAPSS-1 and PAPSS-2. These two enzymes differ in their tissue distribution, with PAPPS-1 mRNA found abundantly in brain and PAPPS-2 highly expressed in the liver (Xu et al., 2000) . These isoforms may also differ in their subcellular localization. Recent evidence suggests that PAPSS-1 has a nuclear localization, as does PAPSS-2 when it is co-expressed with PAPSS-1 (Besset et al., 2000) . Several SNPs have been identified in these genes and functional genomic studies have indicated that two nonsynonymous SNPs are associated with altered capacity to produce PAPS (Xu et al., 2002) . Since SULT activity is ultimately dependent on availability of cofactor, it is appropriate to consider genetic variability in the enzymes producing PAPS when examining SULT pharmacogenetics.
Pharmacogenetics of SULT1A1 and SULT2A1

SULT1A1
SULT1A1 is the most highly expressed hepatic sulfotransferase and this isoform has been reported to sulfate a wide variety of phenolic xenobiotics, as well as iodothyronines (Visser et al., 1998; Kester et al., 1999; Li et al., 2001 ) and the antiangiogenic estrogen metabolite, 2-methoxyestradiol (Spink et al., 2000) . SULT1A1-catalysed biotransformation of 2-methoxyestradiol occurs at physiological concentrations, but while SULT1A1 is capable of sulfating other estrogens at micromolar concentrations (Falany et al., 1994a) , SULT1E1 is responsible for the regulation of estrogen responsiveness at physiological concentrations (Falany et al., 1998; Kotov et al., 1999) . SULT1A1 also catalyses the sulfation of certain N-hydroxy heterocyclic and aromatic amines found in the environment, particularly in meat cooked at high temperatures. In these instances, instead of serving as a detoxification mechanism, sulfation generates a reactive species capable of adducting to cellular macromolecules including DNA, which, if not repaired, can initiate carcinogenesis. Other substrates for SULT1A1 include minoxidil, acetaminophen and the active metabolites of tamoxifen, endoxifen (unpublished data) and 4-hydroxytamoxifen (4-OH TAM) (Nishiyama et al., 2002) . SULT1A1 is expressed in blood platelets, and platelet activity has been demonstrated to correlate with activities in other tissues (Young et al., 1985; Campbell et al., 1987; Sundaram et al., 1989a) . This coordinate regulation of enzyme activity and the accessibility of platelets led to their use as a surrogate for enzyme activity in human population studies. Some studies have shown that SULT1A1 platelet enzymatic activity varies by gender and by season (Marazziti et al., 1995 (Marazziti et al., , 1998 Nowell et al., 2000) . Interestingly, megakaryocytes, parental cells of the platelet, express both estrogen and androgen receptors, leading to the speculation that steroids could modulate the expression of enzymes found in the platelet (Tarantino et al., 1994; Khetawat et al., 2000) . Ethnic variation in platelet enzymatic activity has also been reported. A study by Brittelli et al. (1999) showed that SULT1A1 activity was significantly different between Spaniards and Finns, and in the case of the Finnish population, phenotype also varied by gender. Platelet SULT1A1 phenotype also tends to be higher in African Americans compared to Caucasians (Anderson et al., 1988; Nowell et al., 2000) .
In rodents, Runge-Morris and co-workers demonstrated that expression of SULT1A1 was regulated by glucocorticoids via the glucocorticoid receptor (Duanmu et al., 2001; Fang et al., 2003) . In humans, however, glucocorticoids do not control transcription of SULT1A1. Human SULT1A1 lacks a TATA-box and recent examination of the promoter region has shown that promoter activity is dependent on the presence of SP-1 and Ets transcription factor binding sites, which are located À112 bp upstream of the transcription start site (Hempel et al., 2004) . The authors postulate that the widespread tissue distribution of SULT1A1 is indicative of its importance in the activation/detoxification of xenobiotics entering the body through the gut, skin and liver and that its control by ubiquitous transcription factors may ensure the constant expression of SUL-T1A1. However, SULT1A1 activity varies several-fold among individuals and shows a strong familial segregation (Van Loon and Weinshilboum, 1984) . We have recently described several SNPs in the SULT1A1 promoter region, which are associated with platelet enzymatic activity (Ning et al., 2005) . Four common and one rare SNP are found within a 400 bp region beginning at À693 and are located where they could disrupt transcription factor binding (Table 1) . These SNPs were in linkage disequilibrium with each other and with an SNP at 638, which is responsible for an aminoacid change from arginine to histidine at residue 213 (Raftogianis et al., 1997; Ozawa et al., 1998) . When haplotypes are constructed, the frequency of the haplotypes in different populations varies considerably (Table 2) . Nonetheless, whether these SNPs are examined individually or in haplotypes, they account for only a small percentage of the variation observed in platelet activity. It is possible that other SNPs further upstream of the transcription start site contribute to the variation in activity, or that as yet unidentified environmental exposures can differentially modulate activity. To date, the promoter region SNPs have not been examined in pharmacogenetic studies; however, the coding region SNP, termed SULT1A1*1/*2, has been examined in several molecular epidemiological studies of cancer risk at various sites in the body (reviewed in Glatt and Meinl, 2004) .
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N-desmethyltamoxifen (endoxifen). SULT1A1 is the primary sulfotransferase isoform responsible for the sulfation of 4-OH TAM (Falany et al., 1994b) and endoxifen (unpublished data). Therefore, it is biologically plausible that SULT1A1 genotype could influence overall survival and recurrence of disease in tamoxifen-treated patients. In one study by Nowell et al., the a priori hypothesis was that lower SULT1A1 activity, conferred by the SULT1A1*2 allele, would decrease clearance of 4-OH TAM and increase the efficacy of tamoxifen treatment. However, when SULT1A1 genotype in relation to survival of breast cancer in patients receiving tamoxifen therapy was examined, there was a strong association between survival and the SULT1A1*1 common allele, contrary to the expected outcome if higher activity did in fact result in rapid removal of the drug from the target tissue (Nowell et al., 2002) . A subsequent study in the context of a clinical trial also indicated the same trend of better overall survival associated with the SULT1A1*1 allele (Wegman et al., 2005) in patients treated with tamoxifen. The biological basis for these observations is not fully understood, but preliminary experiments indicate that the sulfated 4-OH TAM metabolite is a potent inducer of apoptosis in breast tumor cell lines (Nowell et al., our unpublished data) . In this case, rapid sulfation of the active metabolites of tamoxifen in breast tumor cells could result in an increase in apoptosis and, hence, improved survival in individuals with the high activity SULT1A1 genotype. Taken together, these studies support a role for SULT1A1 in response to tamoxifen.
SULT2A1
SULT2A1 is the major SULT isoform involved in the formation of steroid sulfate esters and is capable of sulfating both 3a-and 3b-hydroxysteroids, estrogens, testosterone and aliphatic hydroxyl-containing drugs and xenobiotics (Falany et al., 1995) . SULT2A1 is the isoform responsible for the synthesis of DHEA-sulfate in the fetal adrenal gland as well as the reticular layer of the adult adrenal cortex. Human liver expresses high levels of SULT2A1 and it catalyses the sulfation of bile acids and many dietary xenobiotics and drugs. Humans synthesize large amounts of DHEA-sulfate during fetal development and after adrenarche (Parker, 1999) . DHEA-sulfate can serve as a source of precursor for the synthesis of androgen and estrogen in peripheral tissues (Mortola and Yen, 1990; Arlt et al., 1999) .
Therefore, the presence of variant haplotypes in human tissues possessing alterations in activity or stability may alter the plasma levels of DHEA and DHEA-sulfate thereby altering the conversion of DHEA in tissues. Thomae et al. (2002) have reported the resequencing and analysis of sequence variants in the SULT2A1 gene of 60 Caucasian and African-Americans (AA) DNA samples obtained from the Coriell Cell Repository. A total of 15 SNPs were identified in the 5 0 -flanking region and intron and exon sequences of the SULT2A1 gene sequenced. All 15 SNPs were identified in the AA SULT2A1 genes, whereas only six were present in the Caucasian genes. Only eight of the SNPs were present in exon sequence and three of the SNPs resulted in nucleotide changes in the SULT2A1 protein (Table 3 ). The nonsynonymous SNPs were detected only in the AA DNA samples, suggesting a racial difference in SULT2A1 expression and activity. The allelic frequencies reported by Thomae et al. (2002) in 120 alleles from the Coriell Cell Repositorty are shown in Table 3 . The G187C and G781A variants were present in multiple copies in the Coriell samples whereas only a single A679G variant was detected. Expression of the variant allozymes in COS cells generated enzymes with decreased activity as well as lower levels of expression as compared to wild-type SULT2A1. The variant allozymes have not been expressed and characterized in cells that normally express SULT2A1.
We recently conducted an analysis of the frequencies of the variant alleles in DNA samples obtained from AA men from Arkansas and Alabama failed to detect the A679G variant, suggesting it is a rare allele (Table 3) . The frequencies of the G187C and G781A variants in the AR and AL populations were similar to those reported by Thomae et al. (2002) . The presence of the G187C and G781A variants are tightly linked giving rise to essentially three haplotypes. We found an association between the presence of the SULT2A1 variants with plasma DHEA and DHEA-sulfate levels in normal AA men (Wilborn et al., 2005) . Specifically, AA men possessing at least one copy of both the G187C and G781A variants had a significantly increased DHEA: DHEA-sulfate ratio indicting a lower rate of DHEA sulfation. Since increased free plasma DHEA levels may allow for an increased synthesis of testosterone in peripheral tissues, the association of the SULT2A1 variants with the occurrence of prostate cancer was investigated. However, we found that in 119 AA men (Wilborn et al., 2005) .
PAPPS-1 and PAPPS-2
The obligatory cosubstrate of all SULTs is PAPS. PAPS is synthesized from ATP and SO 4
2À
. In prokaryotic organisms, PAPS is produced by two distinct enzymes, but in eukaryotic organisms, PAPS is the product of one bifunctional enzyme, PAPPS. In humans, two isoforms of PAPPS have been identified, PAPPS-1 and PAPPS-2. The pattern of expression of these isoforms differ according to the tissue examined and it has been shown that subcellular localization can depend on coexpression of the two isoforms (Besset et al., 2000) . The entire coding sequences of both isoforms have been sequenced and functional characterization of identified SNPs have been performed (Xu et al., 2002 (Xu et al., , 2003 . In PAPPS-1, 21 polymorphisms (one insertion-deletion and 20 SNPs) were described (Xu et al., 2003) . Two nonsynonymous SNPs in the coding region of the PAPPS-1 gene alter amino acids 333 (Arg to Cys) and 531 (Glu to Gln). Arg333Cys was only observed in approximately 3% of Caucasians examined and was not found in AfricanAmerican subjects. The Glu531Gln SNP was a rare variant that was only shown in one African-American subject. When transient transfection assays were performed, neither variant resulted in an alteration in basal synthetase activity, but the Glu531Gln variant displayed altered substrate kinetic properties. Examination of the PAPPS-2 isoform revealed 22 SNPs, four of which were nonsynonymous (Xu et al., 2002) . Functional assays demonstrated that two of these (Glu10Lys and Val291-Met) were associated with significantly lowered catalytic activity. However, these SNPs occured at low frequency in the 90 Coriell Polymorphism Discovery Resources DNA (0.6 and 1.7%, respectively). The low occurrence of functional SNPs in both PAPPS-1 and PAPPS-2 highlight the importance of the PAPS supply in humans. Consequently, when functional SNPs are present in PAPPS isoforms, combined with the presence of functional SNPs in specific SULTs, certain metabolic pathways could be significantly impacted.
Summary
Sulfotransferases are an important component in the control of cellular homeostasis by either detoxifying potentially harmful xenobiotics or regulating the level of hormones in hormone-responsive tissues. While pharmacogenetic studies of SULTs have lagged behind other enzyme families, it is becoming increasingly apparent that phase II drug metabolism plays an important role in response to therapeutic agents. The elucidation of the impact of genetic variability on enzyme function and the characterization of these effects in different ethnic groups will greatly aid clinicians in estimating risk of toxicity and, ultimately, therapeutic efficacy.
